The phrase "advent of recombinant" is correct and usable in written English.
It can be used in contexts discussing the introduction or arrival of recombinant technology or methods, particularly in fields like genetics or biotechnology.
Example: "The advent of recombinant DNA technology has revolutionized the field of genetic engineering."
Alternatives: "arrival of recombinant" or "introduction of recombinant".
The advent of recombinant DNA technology provides an alternative strategy to improve productivity and yield by strain engineering.
With the advent of recombinant DNA technology in the 1970s, it became possible for scientists to create transgenic clones clones with genomes containing pieces of DNA from other organisms.
The advent of recombinant DNA technology enabled heterologous gene expression in living cells and there large-scale production of protein therapeutics.
With the advent of recombinant DNA technology, antibody genes can be amplified and selected through phage display, cell surface display, or cell-free display systems.
The advent of recombinant DNA technology, development of infectious cDNA clones of RNA viruses, and reverse genetic technologies have revolutionized how viruses are studied.
In the mid-1970s, the advent of recombinant DNA technology spawned a radical new era in the treatment of disease and the role of biologics and their manufacture.
Anthracycline cardiotoxicity has attracted renewed interest with the advent of trastuzumab, a recombinant humanized mAb against the product of the HER2 (erbB2, neu) proto-oncogene [ 12].
With the advent and clinical application of recombinant chemical and cellular mediators of wound healing and a better understanding of the importance of serial debridement, most foot wounds can be healed with little morbidity.
However, as Charles Piller and Keith Yamamoto point out in this highly informative and disturbing book, the recent advent of biotechnology--particularly the techniques of recombinant DNA--has revived the military's interest in biological warfare.
The advent of molecular techniques allowing the production of recombinant proteins has provided a number of candidate antigens that could overcome the problems associated with the use of crude parasite extracts in the serological assays.
Determination of HER2 status has now become of major clinical importance with the advent of anti-HER2 therapy, the recombinant humanised anti-p185Her-2/neu anti-p185Her-2/neu anti-p185Her-2/neugrantibody, 1998; Cobleigh etrastuzumab Slamon et al, 2001).
